Objective: To examine the effects on growth of long-term pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), we present findings from an ongoing 5-year study of the efficacy and safety of treatment with atomoxetine.
Methods: North American patients, 6-17 years old at study entry (N = 1,312) and with Diagnostic and Statistical Manual of Mental Disorders,4th edition (DSM-IV) ADHD, were studied under open-label atomoxetine treatment. Sixty-one were studied up to 5 years.
Results: After 1 month's treatment, patients weighed less than expected from their starting percentiles relative to population norms, with a maximum shortfall at 15 months and a return to expected weight by 36 months. Patients were slightly shorter than expected after 12 months, reaching a maximum shortfall at 18 months and returning to expected height by 24 months. Patients in the top quartile for body mass index (BMI) or weight at baseline, and those in the third quartile for height, showed 5-year decreases from expected values. Those below median height at baseline showed increases relative to expected values.
Conclusions: These interim results indicate that continuous atomoxetine treatment for up to 5 years has little or no long-term effect on juvenile growth and final stature for most patients, although persistent decreases from expected may occur in some patients who are larger than average before treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/cap.2006.0100 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gender-stratified national mental health norms of BSI-53, BSI-18, SCL-10, ADHD-9, and ADHD-6 for Denmark.
Nord J Psychiatry
December 2024
Department of Psychiatry, Psychiatric Centre Copenhagen, Copenhagen, Denmark.
Background: Reliable gender-sensitive normative data is needed to facilitate mental health research and clinical utility of commonly used symptoms scales. This study establishes Danish gender-stratified norms for the 53-item and 18-item Brief Symptom Inventory (BSI-53, BSI-18), proposed attention deficit hyperactivity disorder (ADHD) symptomatology scales from the BSI-53, and the 10-item Symptom Checklist (SCL-10). This study also examines gender-differences in symptom reporting of the ADHD and SCL-10 scales, and assesses potential bias in recent SCL-10 norms.
View Article and Find Full Text PDFAltered trial-to-trial responses to reward outcomes in KCNMA1 knockout mice during probabilistic learning tasks.
Behav Brain Funct
December 2024
Department of Pharmacology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
The large-conductance calcium- and voltage-activated potassium (BK) channels, encoded by the KCNMA1 gene, play important roles in neuronal function. Mutations in KCNMA1 have been found in patients with various neurodevelopmental features, including intellectual disability, autism spectrum disorder (ASD), or attention deficit hyperactivity disorder (ADHD). Previous studies of KCNMA1 knockout mice have suggested altered activity patterns and behavioral flexibility, but it remained unclear whether these changes primarily affect immediate behavioral adaptation or longer-term learning processes.
View Article and Find Full Text PDFAn Evaluation of Whether Routine QTc Interval Screening Is Necessary Prior to Starting ADHD Medications: Experience from a Large Retrospective Study.
Pediatr Rep
December 2024
Department of Pediatric Neurology, Queen Rania Children's Hospital, Royal Medical Services, Amman 11118, Jordan.
Background/objectives: Routine screening electrocardiograms (ECGs) prior to starting medications for attention-deficit/hyperactivity disorder (ADHD) remain controversial. This real-world study assessed corrected QT (QTc) interval data from pediatric patients who had a baseline ECG performed prior to initiating treatment with ADHD medications and ≥6 months of clinical follow-up.
Methods: A retrospective chart review of children aged 2-18 years diagnosed with ADHD with/without autism spectrum disorder (ASD) at child neurology clinics in Jordan (June 2019 and June 2021) was performed, and children were prescribed with ADHD medications to manage symptoms.
Temporal and Fronto-Central Auditory Evoked Responses in Children with Neurodevelopmental Disorders: A Scoping Review.
NeuroSci
December 2024
Audiology Program, School of Rehabilitation Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, ON K1S 5L5, Canada.
At the cortical level, the central auditory neural system (CANS) includes primary and secondary areas. So far, much research has focused on recording fronto-central auditory evoked potentials/responses (P1-N1-P2), originating mainly from the primary auditory areas, to explore the neural processing in the auditory cortex. However, less is known about the secondary auditory areas.
View Article and Find Full Text PDFPrescription psychostimulant use, admissions and treatment initiation and retention in pregnant people with opioid use disorder.
Nat Ment Health
July 2024
Department of Family/Community Medicine and Health and Outcomes Research, Saint Louis University School of Medicine, St. Louis, MO, USA.
While attention deficit hyperactivity disorder is common among people with addiction, the risks and benefits of attention deficit hyperactivity disorder medication in pregnant people with opioid use disorder are poorly understood. Here, using US multistate administrative data, we examined 3,247 pregnant people initiating opioid use disorder treatment, of whom 5% received psychostimulants. Compared to peers not receiving psychostimulants, the psychostimulant cohort had greater buprenorphine (adjusted relative risk 1.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!